Adapted Onco-Esthetics sessions: Patient will received three sessions of Adapted Onco-Esthetics
Study summary
Treatment for cancers of the pharyngolarynx is mutilating, with major consequences for patients' lives in terms of physical and functional after-effects. The psycho-social consequences are also significant, notably the metamorphosis of identity linked to the disease and its treatment, which alters the patient's self-image.
Initial feedback from patients who have been able to benefit from adapted oncoesthetics (OEA) is overwhelmingly positive.
This study will assess the feasibility of oncoesthetics and describe any obstacles.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patient aged 18 or over
* Neoplastic location: oropharynx, oral cavity, hypopharynx, larynx, nasal cavity, salivary glands, cavum, sinus.
* Patient due to start oncological treatment (recurrence authorized)
* Patient fluent in French.
* Affiliation with a social security scheme
* Signature of informed consent prior to any specific procedure linked to the study
* Treatment with curative intent
Exclusion Criteria:
* Breast-feeding or pregnant patient
* Any associated medical or psychological condition that could compromise the patient's ability to participate in the study
* Patient deprived of liberty, under guardianship, or subject to a legal protection measure or unable to express their consent.
* Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons.
Primary outcome measure(s)
Evaluate, in patients treated for cancer of the upper aerodigestive tract, the impact of early treatment with Adapted Onco-Esthetics — At each session (first , second and third). An interval of one to 4 weeks between 2 sessions is permitted Evaluation of the proportion of patients reporting no worsening of self-image representation, as measured by the BIS body image scale.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
